The Relationship of miRNA-155 Expression with B-cell activating factor (BAFF) Level in Systemic lupus erythematosus patients
Al-Furat Journal for Health and Medical Sciences · 15.06.2026 · 2 (2) · 408-418
DOI: 10.46649/vw428j87 ↗Kurz gefasst
Fachartikel in der Zeitschrift Al-Furat Journal for Health and Medical Sciences, online erschienen am 15.06.2026. Verfasst von Zainab Mohammad Hussein und 1 weiteren Autor:innen.
Abstract (Originalsprache)
The multisystemic autoimmune illness known as systemic lupus erythematosus is typified by autoantibodies against nuclear antigens. Tiny (~22 nt) noncoding RNAs called microRNAs control the stability and translation of messenger RNAs. The survival, growth, and function of B cells depend on the cytokine B-cell activating factor, a member of the tumor necrosis factor family. Consequently, both microRNAs and the B-cell activating factor play pivotal role in the pathophysiology of systemic lupus erythematosus. Assessing the amount of microRNA-155 and its correlation with the B-cell activating factor in serum in both healthy controls and systemic lupus erythematosus patients in order to ascertain their possible application as biomarkers for the diagnosis of the illness. A total of 150 individuals (10 men and 140 females, aged 12–60 years) were enrolled and split into two groups: 50 healthy controls and 100 systemic lupus erythematosus patients. Patients were recruited from the Rheumatology Consulting Clinic and the Biological Injection Unit at Marjan Teaching Hospital in Babil Governorate, Iraq. The study was conducted from October 1, 2025, to January 31, 2026. Quantitative reverse transcription polymerase chain reaction revealed that microRNA-155 expression levels were significantly higher in systemic lupus erythematosus patients (fold change = 3.36) compared to the control group (fold change = 0.95; P< 0.001). Similarly, enzyme-linked immunosorbent assay results showed that the B-cell activating factor concentrations were significantly elevated in systemic lupus erythematosus patients (0.62 μg/L) compared to controls (0.38 μg/L; P< 0.001). Patients with systemic lupus erythematosus had greater levels of the B-cell activating factor and microRNA-155 expression, which can be utilized as an early predictive biomarker for disease activity.
Zitieren
APA
Hussein, Z. M., & Ali, A. J. M. (2026). The Relationship of miRNA-155 Expression with B-cell activating factor (BAFF) Level in Systemic lupus erythematosus patients. Al-Furat Journal for Health and Medical Sciences, 2(2), 408-418. https://doi.org/10.46649/vw428j87
Vancouver
Hussein ZM, Ali AJM. The Relationship of miRNA-155 Expression with B-cell activating factor (BAFF) Level in Systemic lupus erythematosus patients. Al-Furat Journal for Health and Medical Sciences. 2026;2(2):408-418. doi:10.46649/vw428j87
BibTeX
@article{Hussein2026,
author = {Hussein, Zainab Mohammad and Ali, Angham Jasim Mohammed},
title = {The Relationship of miRNA-155 Expression with B-cell activating factor (BAFF) Level in Systemic lupus erythematosus patients},
journal = {Al-Furat Journal for Health and Medical Sciences},
year = {2026},
volume = {2},
number = {2},
pages = {408--418},
doi = {10.46649/vw428j87}
}
EUVIMED